Isatuximab

艾沙妥昔单抗

Report date: 2026/05/05 20:00:16

Base Information

Drug NameIsatuximab
Drug Alias NameIsatuximab-Irfc艾萨妥昔单抗isatuximabumIsatuximabum-IRFCSarclisa +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsApoptosis stimulants +[5] 
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsSatiety ResponseNauseaDiarrhea +[29] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2020/03/02
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesImmunogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityAssistance Publique Hopitaux De ParisSanofi +[16] 
Inactive CompaniesN/A
Active IndicationsSatiety ResponseNauseaDiarrhea +[22] 
Inactive IndicationsAnemia, Hemolytic, AutoimmuneProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 

Other Information

ATC CodeL01
Related LinksWikipediaDrugBankKEGG